Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

Despite recent treatment improvements, multiple myeloma remains an incurable disease. Since antibody-dependent cell-mediated cytotoxicity is an important effector mechanism of daratumumab, we explored the possibility of improving daratumumab-mediated cell-mediated cytotoxicity by blocking natural ki...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Haematologica
Autors principals: Nijhof, Inger S., van Bueren, Jeroen J. Lammerts, van Kessel, Berris, Andre, Pascale, Morel, Yannis, Lokhorst, Henk M., van de Donk, Niels W.C.J., Parren, Paul W.H.I., Mutis, Tuna
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2015
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803142/
https://ncbi.nlm.nih.gov/pubmed/25510242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.117531
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars